Merck has named David Weinreich, MBA, as Global Head of Research and Development and Chief Medical Officer for its Healthcare business sector. A seasoned biopharma executive, Weinreich brings over two decades of experience in drug development, having led the successful approval of 15 therapies across multiple indications worldwide.
David joins Merck from Foresite Labs & Foresite Capital Management, where he served as Operating Partner and Senior Advisor. His previous roles include Executive Vice President, Head of Global Clinical Development at Regeneron and Corporate Senior Vice President, Head of Global Development Specialty Medicine at Bayer.
He has also founded several companies and held leadership roles as a venture capitalist, board member and biotech CEO.
Danny Bar Zohar, Member of the Executive Board of Merck and CEO Healthcare, said: “Scientific innovation is the engine that drives everything we do to transform patient care. In David, we have a leader with a unique combination of deep scientific expertise, immense experience in drug development and successfully bringing drugs to the finish line, and global perspective.”
David will oversee global R&D and Medical Affairs for Merck’s Healthcare division. He has extensive experience managing complex pipelines and leading global teams, with a focus on delivering therapies that offer meaningful value to patients and drive sustainable innovation.
He said: “Joining Merck at such a pivotal moment in its growth journey offers a rare opportunity to lead scientific innovation with the potential to have a profound impact on patients’ lives.”
